BMS-299897

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 510225

CAS#: 290315-45-6

Description: BMS-299897 is a gamma-secretase inhibitor that has the potential for treatment of Alzheimer's disease.


Price and Availability

Size
Price

Size
Price

Size
Price

BMS-299897, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 510225
Name: BMS-299897
CAS#: 290315-45-6
Chemical Formula: C24H21ClF3NO4S
Exact Mass: 511.08319
Molecular Weight: 511.94
Elemental Analysis: C, 56.31; H, 4.13; Cl, 6.93; F, 11.13; N, 2.74; O, 12.50; S, 6.26


Synonym: BMS299897; BMS 299897; BMS-299897.

IUPAC/Chemical Name: (R)-4-(2-(1-(4-chloro-N-(2,5-difluorophenyl)phenylsulfonamido)ethyl)-5-fluorophenyl)butanoic acid

InChi Key: IZAOBRWCUGOKNH-OAHLLOKOSA-N

InChi Code: InChI=1S/C24H21ClF3NO4S/c1-15(21-11-7-18(26)13-16(21)3-2-4-24(30)31)29(23-14-19(27)8-12-22(23)28)34(32,33)20-9-5-17(25)6-10-20/h5-15H,2-4H2,1H3,(H,30,31)/t15-/m1/s1

SMILES Code: O=C(O)CCCC1=CC(F)=CC=C1[C@H](N(C2=CC(F)=CC=C2F)S(=O)(C3=CC=C(Cl)C=C3)=O)C


Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
  
 
 


References

1: Meunier J, Villard V, Givalois L, Maurice T. The γ-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Aβ1-42 seeding and short-term memory deficits in the Aβ25-35 mouse model of Alzheimer's disease. Eur J Pharmacol. 2013 Jan 5;698(1-3):193-9. doi: 10.1016/j.ejphar.2012.10.033. Epub 2012 Nov 2. PubMed PMID: 23123349.

2: Zheng M, Wang J, Lubinski J, Flint OP, Krishna R, Yao M, Pursley JM, Thakur A, Boulton DW, Santone KS, Barten DM, Anderson JJ, Felsenstein KM, Hansel SB. Studies on the pharmacokinetics and metabolism of a gamma-secretase inhibitor BMS-299897, and exploratory investigation of CYP enzyme induction. Xenobiotica. 2009 Jul;39(7):544-55. doi: 10.1080/00498250902928555. PubMed PMID: 19480557.

3: Xue YJ, Pursley J, Arnold M. Liquid-liquid extraction of strongly protein bound BMS-299897 from human plasma and cerebrospinal fluid, followed by high-performance liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal. 2007 Apr 11;43(5):1728-36. Epub 2007 Jan 3. PubMed PMID: 17204392.

4: Zhang D, Hanson R, Roongta V, Dischino DD, Gao Q, Sloan CP, Polson C, Keavy D, Zheng M, Mitroka J, Yeola S. In vitro and in vivo metabolism of a gamma-secretase inhibitor BMS-299897 and generation of active metabolites in milligram quantities with a microbial bioreactor. Curr Drug Metab. 2006 Dec;7(8):883-96. PubMed PMID: 17168689.

5: Anderson JJ, Holtz G, Baskin PP, Turner M, Rowe B, Wang B, Kounnas MZ, Lamb BT, Barten D, Felsenstein K, McDonald I, Srinivasan K, Munoz B, Wagner SL. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol. 2005 Feb 15;69(4):689-98. Epub 2005 Jan 7. PubMed PMID: 15670587.